David Amsellem

Ram Selvaraju

Jeff Hung

Stacy Lee

Yale Jen

Annabel Samimy

Annabel Sammy

- Evofem Biosciences announced the conclusion and impact of its August 2025 "Say Vagina" campaign, which generated over **2.5 million views** across social media platforms and led to a **130% increase** in traffic to PHEXXI.com.  **[1618835_20250911LA71451:0]** 
- The campaign also resulted in PHEXXI® becoming the **#1 most followed contraceptive brand** on social media by healthcare providers.  **[1618835_20250911LA71451:0]** 
- Evofem plans to launch SayVaginaStore.com in September, with **100% of proceeds** from Say Vagina Month items donated to charity.  **[1618835_20250911LA71451:0]** 
- The company filed a Definitive Proxy on September 8, 2025, for a Special Meeting on September 26, 2025, where stockholders will vote on a proposal to approve a **merger agreement** with Adifem, Inc., a wholly owned subsidiary of **Aditxt, Inc.**.  **[1618835_20250911LA71451:1]**

Evofem Biosciences Reports "Say Vagina" Campaign Impact and Merger Details

- Evofem Biosciences, Inc. entered into a **Sixth Amendment** to its Amended and Restated Agreement and Plan of Merger with Aditxt, Inc. and Adifem, Inc. on **August 26, 2025**.  **[1618835_0001641172-25-025530_ex2-1.htm:0]** **[1618835_0001641172-25-025530_form8-k.htm:1]** 
- This amendment updated the definition of "Unconverted Company Preferred Stock" to include Series G-1 Convertible Preferred Stock, clarified that the Company will assist in obtaining agreements to exchange Company convertible notes and purchase rights for an aggregate of **not more than 89,021 shares of Parent Preferred Stock**, and set limits for dissenting shares at **5,932,818** common shares and **202** preferred shares.  **[1618835_0001641172-25-025530_ex2-1.htm:0]** **[1618835_0001641172-25-025530_form8-k.htm:1]** 
- Additionally, on **August 22, 2025**, Evofem Biosciences, Inc. converted **$1,573,000** in senior secured convertible notes into **1,573 shares of Series G-1 Convertible Preferred Stock**.  **[1618835_0001641172-25-025530_form8-k.htm:1]**

Evofem Biosciences (EVFM)